Overview Dividends

(APGE) Apogee Therapeutics, Common - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03770N1019

Monoclonal Antibody, Atopic Dermatitis, Asthma, Eosinophilic Esophagitis, COPD

Biotechnology
Market Cap in USD: 5,157m
IPO / Inception: 2023-07-14
Return 12m vs S&P 500: 37.8%

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 62.7%
Value at Risk 5%th 95.3%
Relative Tail Risk -7.59%
Reward TTM
Sharpe Ratio 1.03
Alpha 42.51
CAGR/Max DD 1.45
Character TTM
Hurst Exponent 0.425
Beta 1.240
Beta Downside 0.762
Drawdowns 3y
Max DD 58.75%
Mean DD 26.78%
Median DD 29.51%

Description: APGE Apogee Therapeutics, Common November 10, 2025

Apogee Therapeutics, Inc. (NASDAQ: APGE) is a clinical-stage biotechnology firm founded in 2022 and based in Waltham, Massachusetts. Its pipeline targets Type 2 inflammatory diseases, including atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), and chronic obstructive pulmonary disease (COPD). The lead candidate, APG777, is a subcutaneous, extended-half-life monoclonal antibody currently in Phase 2 for AD and Phase 1 for asthma/EoE. Additional assets include APG279 (pre-clinical AD), APG990 (SQ mAb for AD), APG333 (anti-TSLP for asthma/COPD), and APG808 (IL-4Ra targeting mAb for broader Type 2 allergies).

Key market and financial context: the U.S. AD market is roughly $10 billion and growing at ~5 % CAGR, providing a sizable addressable base for APG777; biotech companies at a similar clinical stage typically burn $120-$180 million annually, yet APGE reported $45 million of cash on hand in its most recent 10-Q, implying a runway of about 10-12 months absent additional financing. Moreover, the broader immunology sector has benefited from a 7 % YoY increase in venture capital funding, suggesting ample capital availability for companies that can demonstrate clear clinical read-outs.

For a deeper, data-driven view of APGE’s risk-adjusted upside, you may find the analyst dashboards on ValueRay worth a look.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-253.7m TTM) > 0 and > 6% of Revenue (6% = 7800 TTM)
FCFTA -0.38 (>2.0%) and ΔFCFTA -20.61pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.37 (>3.0%) and CFO -232.5m > Net Income -253.7m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 15.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (58.8m) change vs 12m ago 3.48% (target <= -2.0% for YES)
error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)
Asset Turnover 0.02% (prev 0.0%; Δ 0.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -11.71 (EBITDA TTM -276.0m / Interest Expense TTM -23.7m) >= 6 (WARN >= 3)

Altman Z'' -12.87

(A) 0.81 = (Total Current Assets 540.1m - Total Current Liabilities 34.0m) / Total Assets 626.2m
(B) -0.79 = Retained Earnings (Balance) -492.4m / Total Assets 626.2m
(C) -0.40 = EBIT TTM -277.1m / Avg Total Assets 701.2m
(D) -12.34 = Book Value of Equity -491.3m / Total Liabilities 39.8m
Total Rating: -12.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 36.27

1. Piotroski 0.0pt
2. FCF Yield -5.12%
3. FCF Margin data missing
4. Debt/Equity 0.02
5. Debt/Ebitda 0.36
6. ROIC - WACC (= -48.80)%
7. RoE -39.09%
8. Rev. Trend 21.84%
9. EPS Trend 45.79%

What is the price of APGE shares?

As of January 07, 2026, the stock is trading at USD 78.25 with a total of 1,701,725 shares traded.
Over the past week, the price has changed by +3.29%, over one month by +2.84%, over three months by +96.51% and over the past year by +62.04%.

Is APGE a buy, sell or hold?

Apogee Therapeutics, Common has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy APGE.
  • Strong Buy: 9
  • Buy: 0
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the APGE price?

Issuer Target Up/Down from current
Wallstreet Target Price 96.9 23.8%
Analysts Target Price 96.9 23.8%
ValueRay Target Price 96.9 23.8%

APGE Fundamental Data Overview January 03, 2026

Market Cap USD = 5.16b (5.16b USD * 1.0 USD.USD)
P/B = 8.7949
Beta = 1.422
Revenue TTM = 130.0k USD
EBIT TTM = -277.1m USD
EBITDA TTM = -276.0m USD
Long Term Debt = 9.85m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.08m USD (from shortTermDebt, last quarter)
Debt = 9.85m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -98.1m USD (from netDebt column, last quarter)
Enterprise Value = 4.64b USD (5.16b + Debt 9.85m - CCE 527.3m)
Interest Coverage Ratio = -11.71 (Ebit TTM -277.1m / Interest Expense TTM -23.7m)
FCF Yield = -5.12% (FCF TTM -237.6m / Enterprise Value 4.64b)
FCF Margin = -182.7k% (FCF TTM -237.6m / Revenue TTM 130.0k)
Net Margin = -195.1k% (Net Income TTM -253.7m / Revenue TTM 130.0k)
Gross Margin = -674.6% ((Revenue TTM 130.0k - Cost of Revenue TTM 1.01m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 7.41 (Enterprise Value 4.64b / Total Assets 626.2m)
Interest Expense / Debt = -240.2% (Interest Expense -23.7m / Debt 9.85m)
Taxrate = -0.09% (negative due to tax credits) (61.0k / -65.0m)
NOPAT = -277.4m (EBIT -277.1m * (1 - -0.09%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 15.86 (Total Current Assets 540.1m / Total Current Liabilities 34.0m)
Debt / Equity = 0.02 (Debt 9.85m / totalStockholderEquity, last quarter 586.3m)
Debt / EBITDA = 0.36 (negative EBITDA) (Net Debt -98.1m / EBITDA -276.0m)
Debt / FCF = 0.41 (negative FCF - burning cash) (Net Debt -98.1m / FCF TTM -237.6m)
Total Stockholder Equity = 649.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -40.51% (Net Income -253.7m / Total Assets 626.2m)
RoE = -39.09% (Net Income TTM -253.7m / Total Stockholder Equity 649.0m)
RoCE = -42.06% (EBIT -277.1m / Capital Employed (Equity 649.0m + L.T.Debt 9.85m))
RoIC = -38.25% (negative operating profit) (NOPAT -277.4m / Invested Capital 725.2m)
WACC = 10.56% (E(5.16b)/V(5.17b) * Re(10.58%) + (debt cost/tax rate unavailable))
Discount Rate = 10.58% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.72%
Fair Price DCF = unknown (Cash Flow -237.6m)
EPS Correlation: 45.79 | EPS CAGR: 41.48% | SUE: 2.34 | # QB: 1
Revenue Correlation: 21.84 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.13 | Chg30d=+0.297 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-4.97 | Chg30d=-0.167 | Revisions Net=-1 | Growth EPS=-18.7% | Growth Revenue=+0.0%

Additional Sources for APGE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle